Early Seroreversion After 2 Doses of Hepatitis A Vaccination in Human Immunodeficiency Virus–Positive Patients: Incidence and Associated Factors

Sung‐Hsi Huang, Chung‐Hao Huang, Ning‐Chi Wang, Tun‐Chieh Chen, Yuan‐Ti Lee, Shih‐Ping Lin, Te‐Yu Lin, Chi‐Ying Lin, Yu‐Lin Lee, Chen‐Hsiang Lee, Cheng‐Pin Chen, Kuan‐Yin Lin, Guan‐Jhou Chen, Chun‐Eng Liu, Shu‐Hsing Cheng, Po‐Liang Lu, Chia‐Jui Yang, Chien‐Ching Hung, on behalf of the Taiwan HIV Study Group – 7 January 2019 – Serological responses (Seroresponse) and durability of hepatitis A virus (HAV) vaccination are reduced among human immunodeficiency virus (HIV)‐positive patients.

Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand

Luis Calzadilla‐Bertot, Gary P. Jeffrey, Bryon Jacques, Geoffrey McCaughan, Michael Crawford, Peter Angus, Robert Jones, Edward Gane, Stephen Munn, Graeme Macdonald, Jonathan Fawcett, Alan Wigg, John Chen, Michael Fink, Leon A. Adams – 4 January 2019 – The worldwide increase in obesity and diabetes has led to predictions that nonalcoholic steatohepatitis (NASH) will become the leading indication for orthotopic liver transplantation (OLT). Data supporting this prediction from outside the United States are limited.

Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis

Zita Galvin, Ramraj Rajakumar, Emily Chen, Oyedele Adeyi, Markus Selzner, David Grant, Gonzalo Sapisochin, Paul Greig, Mark Cattral, Ian McGilvray, Anand Ghanekar, Nazia Selzner, Les Lilly, Keyur Patel, Mamatha Bhat – 4 January 2019 – Nonalcoholic fatty liver disease (NAFLD) can occur de novo in patients undergoing liver transplantation (LT) for indications other than NAFLD, and it has been increasingly recognized as a complication in the post‐LT setting.

Subscribe to